Axion BioSystems to Sell Direct in Europe

Xenter, Inc. Appoints 4 Industry Leaders to Board of Directors; Closes $12M Series A

Xenter’s first product, which the company will announce shortly, is a medical device that not only combines the function of multiple existing devices but will also revolutionize the field of interventional medicine by producing valuable Physical Intelligence™ data and enabling advanced Artificial Intelligence solutions, leading to improved patient outcomes while reducing the cost, complexity and invasiveness of cardiac procedures.

Indivumed Partners with Oslo University Hospital to Advance Cancer Research

By scanning high-resolution images of haematoxylin and eosin-stained tumor section slides for all IndivuType cases, Indivumed will be able to leverage an entirely new dimension of data in the coming months.

Harold Hill Joins NeuX Technologies as Director of Corporate Accounts

Harold Hill is a retired Special Forces Medic, serving 26 years, and led the medical department for a Special Missions Unit within the United States Special Operations Command

Effective July 1, 2017:  Axion BioSystems and Nanion Technologies have enjoyed a very productive relationship over the past three years, with Nanion acting as sole distributor of Axion products in Europe. Nanion has effectively penetrated the high-throughput microelectrode array (MEA) market in Europe, while rapidly growing their existing business. Since both companies are undergoing rapid growth, it has been mutually decided that the best approach for both companies is to focus on commercializing their respective product lines.

Tom O’Brien, Axion’s President and CEO, “We have been pleased with the energy and enthusiasm Nanion invested in Axion’s products.”  “It is through Nanion’s efforts that we have been able to build a sizable install base of Maestro multiwell MEA systems in Europe. In order to continue this growth trajectory, Axion will establish a larger, dedicated team in Europe focused on sales and applications support,” concluded O’Brien.

Nanion has recently moved into a new, larger space anticipating ongoing growth. According to Niels Fertig, Nanion’s CEO, “we are facing increasing demand for our existing products. Furthermore, we continue to create innovative new products that address needs in life science research. We feel it is once again time for us to focus on products developed by the Nanion team.”

Effective July 1, 2017 Axion products will be sold through Axion BioSystems International. Nanion and Axion will continue to work together through December 31, 2017 to ensure a smooth transition for existing Axion customers, and those currently working with Nanion to acquire Axion products in 2017.




Subscribe to Medical Device News Magazine

Related Articles